Day ThreeThursday, 26 March 2026 - Western European Summer Time (WEST)

Securing appropriate reimbursement has become as critical to commercial success as obtaining regulatory approval, yet many medtech innovations struggle to achieve sustainable coverage and payment. Our panel of experts discuss how companies can integrate reimbursement considerations into their earliest development decisions to avoid costly pivots later. With healthcare systems worldwide under increasing economic pressure, new technologies face rigorous assessment of their economic value alongside clinical benefits. The discussion will examine how successful companies are navigating the fragmented European reimbursement landscape while building evidence packages that resonate with both public and private payers across different healthcare systems.

• Incorporating reimbursement considerations into early product development, including feature decisions, clinical endpoints, and economic value demonstration
• Navigating country-specific approaches in the fragmented European market, where coverage decisions, assessment methodologies, and payment levels vary significantly
• Building evidence packages that support reimbursement claims through appropriate study design, economic modelling, and stakeholder engagement strategies

Few medtech companies can internally master all the specialized capabilities required to bring complex medical technologies from concept to market. This practical panel explores how, and when, to work with external partners across the development journey, from contract manufacturing to clinical research organizations and specialized consultants. The discussion will address the critical decisions around which functions to keep in-house versus outsource, how to select partners aligned with your company's stage and needs, and how to structure relationships that deliver value while managing costs. With the right partnership ecosystem, even small companies can access world-class capabilities while maintaining focus on their core innovation and strategic direction.

• Selecting the right partners for different development phases based on capability alignment, cultural fit, and scalability
• Negotiating smart contracts that protect your interests while creating incentives for partners to deliver exceptional performance
• Balancing in-house capabilities with strategic outsourcing to optimize resource allocation and development timeline

The convergence of miniaturized sensors, improved connectivity, and advanced analytics is enabling a new generation of wearable devices and remote monitoring solutions that extend care beyond traditional settings. These technologies are transforming chronic disease management, post-acute care, and preventive health approaches. As healthcare systems worldwide seek to manage costs while improving outcomes, remote monitoring offers promising solutions for keeping patients healthier at home while generating valuable real-world data. The discussion will address both the technical innovations driving this field and the business models that can make these solutions sustainable.

• Breakthroughs in home monitoring technologies that combine improved sensor accuracy, patient comfort, and meaningful clinical insights
• Integration strategies with existing healthcare systems, including EHR connectivity, clinical workflow incorporation, and data management approaches
• Reimbursement approaches for remote monitoring solutions across different healthcare systems and the evidence needed to support coverage decisions

The leadership requirements for a medtech company evolve dramatically as it progresses from early R&D through clinical validation to commercial operations. This insightful panel examines how successful companies manage these transitions by building teams with the right expertise for each development phase. The discussion will explore when changes in the team may be necessary, requiring honest assessment of capabilities and strategic additions to the leadership team. Drawing on both successful examples and cautionary tales, the panel will provide practical guidance on organizational development, talent acquisition, and leadership evolution in the specialized medtech environment.

• Navigating founder transitions through company growth phases, including when and how to bring in experienced executives
• Building teams optimized for different stages of development, from technical innovation to regulatory approval to commercial execution
• Leadership requirements insights from investors on the evolving skills needed as companies progress from concept to market